Abstract
Photosensitizers are generally treated as key components for photodynamic therapy. In contrast, we herein report an aggregation-induced emission luminogen (AIEgen)-based photosensitizer (TPE-Py-FFGYSA) that can serve as a non-toxic adjuvant to amplify the antitumor efficacy of paclitaxel, a well-known anticancer drug, with a synergistic effect of "0 + 1 > 1". Besides the adjuvant function, TPE-Py-FFGYSA can selectively light up EphA2 protein clusters overexpressed in cancer cells in a fluorescence turn-on mode, by taking advantage of the specific YSA peptide (YSAYPDSVPMMS)-EphA2 protein interaction. The simple incorporation of FFG as a self-assembly-aided unit between AIEgen (TPE-Py) and YSA significantly enhances the fluorescent signal output of TPE-Py when imaging EphA2 clusters in live cancer cells. Cytotoxicity and western blot studies reveal that the reactive oxygen species (ROS) generated by TPE-Py-FFGYSA upon exposure to light do not kill cancer cells, but instead provide an intracellular oxidative environment to help paclitaxel have much better efficacy. This study thus not only extends the application scope of photosensitizers, but also offers a unique theranostic system with the combination of diagnostic imaging and adjuvant antitumor therapy.
Introduction
Precision in both diagnosis and treatment remains a primary goal in oncology. Two major hurdles persist: the difficulty of high-contrast tumor imaging without significant background noise and the inherent or acquired resistance of cancer cells to chemotherapy agents such as paclitaxel (Ptx). Traditional fluorescent dyes often suffer from Aggregation-Caused Quenching (ACQ), where brightness is lost as molecules cluster at the target site. Furthermore, while photodynamic therapy (PDT) utilizes light-activated photosensitizers to generate cytotoxic levels of Reactive Oxygen Species (ROS), these treatments can be difficult to calibrate and may cause off-target damage.
This research presents a novel theranostic system designed to address these challenges. By utilizing an Aggregation-Induced Emission (AIE) luminogen, the system targets specific proteins on cancer cells to "turn on" a fluorescent signal. Crucially, it generates controlled, low levels of ROS that act not as a primary killer, but as a subtle adjuvant to sensitize cells to chemotherapy, achieving a synergistic "0 + 1 > 1" antitumor effect.
Design and Methodology
The research team synthesized a multi-functional molecule, TPE-Py-FFGYSA, consisting of three modular components:
- TPE-Py: An AIE-active luminogen that fluoresces upon restricted molecular rotation, ideal for imaging dense protein clusters.
- FFG Tripeptide: A self-assembly-aided unit that promotes tighter molecular packing at the target, boosting the fluorescent signal.
- YSA Peptide: A targeting moiety specific to the EphA2 receptor, which is overexpressed in many cancer types.
The study employed the human prostate cancer cell line PC-3 (EphA2-positive) and human smooth muscle cells (EphA2-negative) as a control. Experimental validation involved confocal laser scanning microscopy (CLSM) for tracking internalization, MTT assays for cell viability, and Western blot analysis to investigate signaling pathways, specifically the Akt survival pathway.
Results and Discussion
The core conceptual contribution of this work is the "0 + 1 > 1" synergy. The AIE adjuvant alone, at the concentrations used, does not induce cell death (0). Paclitaxel alone exhibits a baseline efficacy (1). However, the combination of the two under light irradiation performs significantly better than the sum of their individual effects (>1).
Key Findings
- Signal Amplification: The addition of the FFG tripeptide increased the fluorescent signal approximately four-fold compared to versions without the spacer, facilitating "surface-induced self-assembly" even at low concentrations.
- Targeting Specificity: CLSM imaging demonstrated that the probe selectively illuminated PC-3 cancer cells while remaining dark in normal smooth muscle cells, successfully monitoring the internalization of EphA2 receptors from the cell membrane to the cytoplasm.
- Chemotherapeutic Potency Boost: The combination of the AIE adjuvant and light irradiation reduced the IC50 of paclitaxel from 75.9 nM to 7.8 nM—a nearly 10-fold increase in drug efficacy.
- Mechanistic Insights: Western blots confirmed that the synergistic effect is rooted in the ROS-mediated inhibition of p-Akt, a key survival signal. By suppressing this mechanism, the cells are left vulnerable to paclitaxel-induced apoptosis, as evidenced by enhanced Cytochrome c release.
Conclusion and Future Outlook
TPE-Py-FFGYSA offers a unique theranostic platform combining diagnostic imaging with adjuvant antitumor therapy. By repurposing ROS as a sensitizer rather than a primary cytotoxic agent, the system enhances the efficacy of existing drugs like paclitaxel while maintaining a high degree of specificity.
While promising, the study was primarily conducted in vitro. Future work must transition to in vivo models to evaluate the system's performance in complex biological environments. Additionally, because the system relies on light activation, its application may be limited by the penetration depth of light in tissue, suggesting potential utility in surface-level tumors or those accessible via endoscopic methods. Future research into near-infrared (NIR) activation could further expand the clinical reach of this technology.
Summary updated